Asan Medical Center | Clinical Trial Center
Status and phase
Conditions
Treatments
About
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in Mild Cognitive Impairment Patients with Cerebrovascular Disease
Full description
Subject will be randomised in a 1:1 ratio to receive either Choline Alfoscerate or it's placebo. Investigational Product(IP, Choline Alfoscerate or it's placebo) will be administered 3 times a day per oral during the treatment
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
418 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Sun U Kwon, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal